Lisofylline suppresses ex vivo release by murine spleen cells of hematopoietic inhibitors induced by cancer chemotherapeutic agents

Experimental Hematology

Volumn 28, Issue 8, 2000, Pages 916-923

  De Vries, Peter ^a   Singer, Jack W ^a  

^a Cell Therapeutics Inc   (United States)

Author keywords

Cancer chemotherapeutic agents; Hematopoietic inhibitors; Lisofylline; Spleen cell conditioned media

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CYTARABINE; CYTOKINE; ETOPOSIDE; GROWTH INHIBITOR; LISOFYLLINE; MACROPHAGE INFLAMMATORY PROTEIN; MELPHALAN; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; COLONY FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GROWTH INHIBITION; HEMATOPOIESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; STRESS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CELL DIVISION; CISPLATIN; COLONY-FORMING UNITS ASSAY; CULTURE MEDIA, CONDITIONED; CYTARABINE; ETOPOSIDE; FEMALE; GROWTH INHIBITORS; HEMATOPOIETIC STEM CELLS; MACROPHAGE INFLAMMATORY PROTEIN-1; MELPHALAN; MICE; MICE, INBRED BALB C; PENTOXIFYLLINE; SPLEEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MURINAE;

EID: 0033832364     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(00)00493-8     Document Type: Article

References (69)

1. Metcalf D (1984) The hematopoietic colony stimulating factors. The Netherlands: Elsevier Science Publishers B.V.
2. Keller J.R., Mantel C., Sing G.K., Ellingsworth L.R., Ruscetti S.K., Ruscetti F.W. Transforming growth factor-1 selectively regulates early murine hematopoietic progenitors and inhibits the growth of IL-3 dependent myeloid leukemic cell lines. J Exp Med. 168:1988;737.
3. Sing G.K., Keller J.R., Ellingsworth L.R., Ruscetti F.W. Transforming growth factor selectively inhibits normal and leukemic bone marrow cell growth in vitro. Blood. 72:1988;1504.
4. Keller J.R., Sing G.K., Ellingsworth L.R., Ruscetti F.W. Transforming growth factor. possible roles in the regulation of normal and leukemic hematopoietic cell growth J Cell Biochem. 39:1989;175.
5. Han Z.C., Bellucci S., Wan H.Y., Caen J.P. New insights into the regulation of megakaryopoiesis by hematopoietic and fibroblast growth factors and transforming growth factor-1. Br J Haematol. 81:1992;1.
6. Ottmann O.G., Pelus L.M. Differential proliferative effects of transforming growth factor-β on human hematopoietic cells. J Immunol. 140:1988;2661.
7. Keller J.R., Jacobsen S.E.W., Dubois C.M., Hestdal K., Ruscetti F.W. Transforming growth factor β a bidirectional regulator of hematopoietic cell growth Int J Cell Cloning. 10:1992;2.
8. Peetre C., Gullberg U., Nilsson E., Olsson I. Effects of recombinant tumor necrosis factor on the proliferation and differentiation of leukemic and normal hematopoietic cells in vitro. J Clin Invest. 78:1988;1694.
9. Murphy M., Perussa B., Trinchiere G. Effects of recombinant tumor necrosis factor, lymphotoxin, and immune interferon on proliferation and differentiation of enriched hematopoietic precursor cells. Exp Hematol. 16:1988;131.
10. Backx B., Broeders L., Bot F.J., Lowenberg B. Positive and negative effects of tumor necrosis factor on colony growth from highly purified normal marrow progenitors. Leukemia. 5:1991;66.
11. Broxmeyer H.E., Williams D.E., Lu L., Cooper S., Anderson S.L., Beyer G.S., Hoffman R., Rubin B.Y. The suppressive influences of human tumor necrosis factor on bone marrow hematopoietic cells from normal donors and patients with leukemia. synergism of tumor necrosis factor and interferon γ J Immunol. 136:1988;4487.
12. - human hematopoietic progenitor cells. J Exp Med. 180:1994;1177.
13. Broxmeyer H.E., Sherry B., Lu L., Cooper S., Oh K., Tekamp-Olsen P., Kwon B.S., Cerami A. Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation in vitro by bone marrow myeloid progenitor cells. Blood. 76:1990;1110.
14. Broxmeyer H.E., Sherry B., Cooper S., Ruscetti F.W., Williams D.E., Arosio P., Kwon B.S., Cerami A. Macrophage inflammatory protein (MIP)-β abrogates the capacity of MIP-1α to suppress myeloid progenitor cell growth. J Immunol. 147:1991;2586.
15. Broxmeyer H.E., Sherry B., Cooper S., Lu L., Maxe R., Beckmann P.M., Cerami A., Ralph P. Comparative analysis of human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. J Immunol. 150:1993;3448.
16. Graham G.J., Wright E.G., Hewick R., Wolpe S.D., Wilkie N.M., Donaldson D., Lorimore S., Pragnell I.B. Identification and characterization of an inhibitor of hematopoietic stem cell proliferation. Nature. 344:1990;442.
17. Gewirtz A.M., Zhang J., Ratajczak J., Ratajczak M., Park K.S., Li C., Yan Z., Poncz M. Chemokine regulation of human megakaryocytopoiesis. Blood. 86:1995;2559.
18. + cells purified from cord blood and fetal liver. Exp Hematol. 23:1995;422.
19. + hematopoietic progenitors to cytokines is determined by the balance between synergy of multiple stimulators and negative cooperation of multiple inhibitors. Exp Hematol. 22:1994;985.
20. Moore M.A.S. Clinical implications of positive and negative hematopoietic stem cell regulators. Blood. 78:1991;1.
21. Dunlop D.J., Wright E.G., Lorimore S., Graham G.J., Holyoake T., Kerr D.J., Wolpe S.D., Pragnell I.B. Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1α in vivo. Blood. 79:1992;221.
22. Kadar E., Sureda A., Mangues M.A., Ingles-Esteve J., Valls A., Garcia J. Serum levels of G-CSF, IL-3, IL-6 and GM-CSF after a single intraperitoneal dose of rhG-CSF in lethally irradiated B6D2F1 mice. Acta Haematol. 98:1997;119.
23. Ho A.D., Maruyama M., Maghazachi A., Mason J.R., Gluck S., Corringham R.E.T. Soluble CD4, soluble CD8, soluble CD25, lymphopoietic recovery and endogenous cytokines after high-dose chemotherapy and blood stem cell transplantation. Blood. 84:1994;3550.
24. Cario M.S., Suen Y., Sender L., Gillian E.R., Ho W., Plunkett J.M., van de Ven C. Circulating granulocyte-colony stimulating factor (G-CSF) levels after allogeneic and autologous bone marrow transplantation. endogenous G-CSF production correlates with myeloid engraftment Blood. 79:1992;1869.
25. Kawano Y., Takaue Y., Saito S., Sato J., Shimizu T., Suzue T., Hirao A., Okamoto Y., Abe T., Watanabe T., Kuroda Y., Kimura F., Motoyoshi K., Asano S. Granulocyte colony-stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage CSF, interleukin 3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts. Blood. 81:1993;856.
26. Rabinowitz J., Petros W.P., Stuart A.R., Peters W.P. Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support. Blood. 81:1993;2452.
27. Haas R., Gericke G., Witt B., Cayeux S., Hunstein W. Increased serum levels of granulocyte colony stimulating factor after autologous bone marrow or blood stem cell transplantation. Exp Hematol. 21:1993;109.
28. Beksac M., Ozcan M., Koc H., Akan H., Ilhan O. Relevance of serum G-CSF levels in bone marrow transplantation patients. Exp Hematol. 22:1994;480.
29. Grace R.J., Kendall R.G., Chapman C., Hartley A.E., Barnard D.L., Norfolk D.R. Changes in serum erythropoietin levels during allogeneic marrow transplantation. Eur J Haematol. 47:1991;81.
30. Schapira L., Antin J.H., Ransil B.J., Antman K.H., Eder J.P., McGarigle C.J., Goldberg M.A. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood. 76:1990;2354.
31. Kyriakis J.M., Banerjee P., Nikolakaki E., Dai T., Rubie E.A., Ahmad M.F., Avruch J., Woodgett J.R. The stress-activated protein kinase subfamily of c-jun kinases. Nature. 369:1994;156.
32. Davis R.J. Mapks. new Jnk expands the group Trends Biochem Sci. 19:1994;470.
33. Woodgett J.R., Avruch J., Kyriakis J. The stress activated protein kinase pathway. Cancer Surv. 27:1996;127.
34. Saleem A., Datta R., Yuan Z.M., Kharbanda S., Kufe D.W. Involvement of stress-activated protein kinase in the cellular response to 1-β-D-arabinofuranosylcytosine and other DNA-damaging agents. Cell Growth Differ. 6:1995;1651.
35. Kharbanda S., Ren R., Pandey P., Shafman T.D., Feller S.M., Weichselbaum R.R., Kufe D.W. Activation of the c-ab1 tyrosine kinase in the stress response to DNA-damaging agents. Nature. 376:1995;785.
36. Kim S.J., Wagner S., Liu F., O'Reilly M.A., Robbins P.D., Green M.R. Retinoblastoma gene product activates expression of the human TGF-β2 gene through transcription factor AFT-2. Nature. 358:1992;331.
37. Rhoades K.L., Golub S.H., Economou J.S. The regulation of the human tumor necrosis factor α promotor region in macrophage, T cell and B cell lines. J Biol Chem. 267:1992;22102.
38. Newell C.L., Deisseroth A.B., Lopez-Berestein G. Interaction of nuclear proteins with AP-1/CRE-like promotor sequence in the human TNF-α gene. J Leukoc Biol. 56:1995;27.
39. Leitmean D.C., Ribero R.C., Mackow E.R., Baxter J.D., West B.L. Identification of a tumor necrosis factor responsive element in the tumor necrosis alpha gene. J Biol Chem. 226:1991;9343.
40. Singer JW, Bianco JA (1998) Modification of regimen-related toxicity. Boston: Blackwell.
41. Iwamoto K.S., McBride W.H. Production of 13-hydroxyoctadecadienoic acid and tumor necrosis factor-α by murine peritoneal macrophages in response to irradiation. Radiat Res. 139:1994;103.
42. Buchanan M.R., Butt R.W., Magas Z., Van Rijn J., Hirsch J., Nazin D.J. Endothelial cells produce a lipoxygenase-derived chemo-repellent which influences platelet-endothelial cell interactions. effect of aspirin and salicylate Thromb Haemost. 53:1985;306.
43. Kaduce T.L., Figard P.H., Leifur R., Spector A.A. Formation of γ-hydroxyoctadecadeinoic acid from linoleic acid in endothelial cells. J Biol Chem. 264:1989;6823.
44. Reinaud O., Delaforge M., Boucher J.L. Oxidative metabolism of linoleic acid by human leukocytes. Biochem Biophys Res Commun. 161:1989;883.
45. Folcik V.A., Cathcart M.K. Predominance of esterified hydroperoxy-linoleic acid in human monocyte-oxidized LDL. J Lipid Res. 35:1994;1570.
46. Abraham E., Bursten S., Shenkar R., Allbee J., Tuder R., Woodson P., Guidot D.M., Rice G.C., Singer J.W., Repine J.E. Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice. J Exp Med. 181:1995;569.
47. Hybertson B.M., Bursten S.L., Leff J.A., Lee Y.M., Jepson E.K., DeWitt C.R., Zagorski J., Cho H.G., Repine J.E. Lisofylline prevents leak, but not neutrophil accumulation, in lungs of rats given IL-1 intratracheally. J Appl Physiol. 82:1997;226.
48. Waxman K., Daughters K., Aswani S., Rice G.C. Lisofylline decreases white cell adhesiveness and improves survival after experimental hemorrhagic shock. Crit Care Med. 24:1996;1724.
49. Clarke E., Rice G.C., Weeks R.S., Jenkins N., Nelson R., Bianco J.A., Singer J.W. Lisofylline inhibits transforming growth factor β release and enhances trilineage hematopoietic recovery after 5-fluorouracil treatment in mice. Cancer Res. 56:1996;105.
50. Teicher B.A., Kakeji Y., Northey D. Lisofylline as an adjuvant to high dose cytotoxic therapy. Int J Cancer. 11:1997;265.
51. Wong J.S., Ara G., Keyes S.R., Herbst R., Coleman C.N., Teicher B.A. Lisofylline as a modifier of radiation therapy. Oncol Res. 8:1996;513.
52. Guidot D.M., Bursten S.L., Rice G.C., Chaney R.B., Singer J.W., Repine A.J., Hybertson B.M., Repine J.E. Modulating phosphatidic acid metabolism decreases oxidative injury in rat lungs. Am J Physiol. 17:1997;957.
53. Bright J., Du C., Coon M., Sriram S., Klaus S. Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation. an effect of the novel anti-inflammatory drug lisofylline J Immunol. 161:1998;7015.
54. Coon M., Diegel M., Leshinsky N., Klaus S. Selective pharmacologic inhibition of murine and human IL-12-dependent Th1 differentiation and IL-12 signaling. J Immunol. 163:1999;6567.
55. Bodine D.M., Crosier P.S., Clark S.C. Effects of hematopoietic growth factors on the survival of primitive stem cells in liquid suspension culture. Blood. 78:1991;914.
56. Wodnar-Filipowicz A., Lyman S.D., Gratwohl A., Tichelli A., Speck B., Nissen C. Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood. 88:1996;4493.
57. Schiffer C.A. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood. 88:1996;3675.
58. Maini A., Morse P.D., Wang C.Y., Jones R.F., Haas G.P. New developments in the use of cytokines for cancer therapy. Anti Cancer Res. 17:1997;3803.
59. Groopman J.E., Molina M., Scadden D.T. Hematopoietic growth factors. N Engl J Med. 321:1988;1449.
60. Bensinger W., Singer J., Appelbaum F., Lilleby K., Longin I., Rowley S., Clarke E., Clift R., Hansen J., Shields T., Storb R., Weaver C., Weiden P., Buckner C.D. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood. 81:1993;3158.
61. Nemunaitis J., Rabinowe S.N., Singer J.W., Bierman P.J., Vose J.M., Freedman A.S., Onetto N., Gillis S., Odette D., Gold M., Buckner C.D., Hansen J., Ritz J., Appelbaum F., Armitge J., Nadler L. Recombinant granulocyte macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 324:1991;1773.
62. Schall T.S. Biology of the RANTES/SIS cytokine family. Cytokine. 3:1991;165.
63. Wolpe S.D., Cerami A. Macrophage inflammatory proteins 1 and 2. members of a novel superfamily of cytokines FASEB J. 3:1989;2565.
64. Miller-Graziano C.L., Szabo G., Griffey K., Metha B., Kodys K., Catalano D. Role of elevated monocyte transforming growth factor (TGF-β) production in post-trauma immunosuppression. J Clin Immunol. 11:1992;95.
65. Clarke E., Rice G.C., Hoy C.A., Bianco J.A., Singer J.W. Induction of hematopoietic regulatory molecules by chemotherapeutic agents. suppression of inhibitory but not stimulatory cytokines by Lisofylline Blood. 86:1995;690A. (abstr).
66. Rice G.C., Rosen J., Weeks R., Michnick J., Bursten S.L., Bianco J.A., Singer J.W. CT-1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo. Shock. 1:1994;254.
67. Sporn M.B., Roberts A.B. Peptide growth factors are multifunctional. Nature. 332:1988;217.
68. Jacobsen S.E.W., Ruscetti F.W., Dubois C.M., Keller J.R. Tumor necrosis factor-α directly and indirectly regulates hematopoietic progenitor cell proliferation. role of colony-stimulating factor receptor modulation J Exp Med. 175:1992;1759.
69. Stone K, Dahlberg S, Luger SM, Bow EJ (2000) A randomized double-blind phase III trial of Lisofylline (LSF) during standard induction in patients (pts) with AML. Am Soc Clin Oncol 2000 (abstr).